Residual Disease after Neoadjuvant Therapy for Breast Cancer: Can MRI Help?

Affiliations

Editorial

Nola M Hylton. Radiology. 2018 Nov.

. 2018 Nov;289(2):335-336.

doi: 10.1148/radiol.2018181846. Epub 2018 Aug 28.

¹ From the Department of Radiology, University of California, San Francisco, 1600 Divisadero St, Room C255, San Francisco, CA 94132.

No abstract available

Comment on

Dynamic Contrast-enhanced Breast MRI for Evaluating Residual Tumor Size after Neoadjuvant Chemotherapy.
Kim SY, Cho N, Park IA, Kwon BR, Shin SU, Kim SY, Lee SH, Chang JM, Moon WK. Kim SY, et al. Radiology. 2018 Nov;289(2):327-334. doi: 10.1148/radiol.2018172868. Epub 2018 Aug 28. Radiology. 2018. PMID: 30152744

1. American College of Radiology . ACR practice parameter for the performance of contrast-enhanced magnetic resonance imaging (MRI) of the breast. https://www.acr.org/-/media/ACR/Files/Practice-Parameters/mr-contrast-br... . Accessed July 29, 2018.
1. McGuire KP, Toro-Burguete J, Dang H, et al. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy? Ann Surg Oncol 2011;18(11):3149–3154. - PubMed
1. De Los Santos JF, Cantor A, Amos KD, et al. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer: Translational Breast Cancer Research Consortium trial 017. Cancer 2013;119(10):1776–1783. - PMC - PubMed
1. Marinovich ML, Macaskill P, Irwig L, et al. Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis. BMC Cancer 2015;15(1):662. - PMC - PubMed
1. U.S. Food and Drug Administration . Guidance for industry pathological complete response in neoadjuvant treatment of high-risk early-stage breast cancer: use as an endpoint to support accelerated approval. https://www.fda.gov/downloads/drugs/guidances/ucm305501.pdf. Accessed July 29, 2018.